<p>隨着亞洲市場在複雜的環境中應對混合的經濟指標和不斷變化的投資者情緒，該地區的科技行業憑藉其高增長潛力繼續吸引關注。在這種環境下，識別有前景的科技股票需要尋找那些在全球趨勢變化和地方挑戰中展現出韌性和創新的公司。</p>
<h3>亞洲十大高增長科技公司</h3>
<table>
<thead>
<tr>
<th>名稱</th>
<th>收入增長</th>
<th>盈利增長</th>
<th>增長評級</th>
</tr>
</thead>
<tbody>
<tr>
<td>盛宜科技有限公司</td>
<td>21.50%</td>
<td>32.87%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>巨人網絡集團</td>
<td>34.73%</td>
<td>40.54%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>福斯特科技</td>
<td>37.83%</td>
<td>51.54%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>蘇州 TFC 光通信</td>
<td>35.80%</td>
<td>36.87%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>金電路電子</td>
<td>29.41%</td>
<td>37.22%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>中基光電</td>
<td>34.82%</td>
<td>35.50%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>盛宜電子</td>
<td>24.67%</td>
<td>33.32%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>eWeLL 有限公司</td>
<td>21.55%</td>
<td>22.80%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>科技發展</td>
<td>35.68%</td>
<td>75.80%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>CARsgen 治療控股</td>
<td>100.40%</td>
<td>118.16%</td>
<td>★★★★★★</td>
</tr>
</tbody>
</table>
<p>點擊這裏查看我們亞洲高增長科技和人工智能股票篩選器的完整 187 只股票列表。</p>
<p>我們將從篩選結果中選取一些進行分析。</p>
<h2>上海 OPM 生物科學（SHSE:688293）</h2>
<p><strong>Simply Wall St 增長評級：</strong> ★★★★☆☆</p>
<p><strong>概述：</strong> 上海 OPM 生物科學有限公司專注於提供細胞培養基和 CDMO 服務，業務覆蓋中國及國際市場，市值為 59 億人民幣。</p>
<p><strong>運營：</strong> OPM 生物科學主要通過其細胞培養基和 CDMO 服務產生收入。該公司在中國和國際市場均有運營，市值為 59 億人民幣。</p>
<p>上海 OPM 生物科學在競爭激烈的生物科技行業中展現出強勁的增長，2025 年前九個月收入顯著增長 25.8%，達到 2.7153 億人民幣，淨收入激增 81.4%，達到 4943 萬人民幣。這些財務收益反映出公司對研發的戰略重視，這對維持技術領導地位和在亞洲高增長市場中的創新至關重要。儘管面臨股價高度波動和預測的股本回報率僅為 7% 的挑戰，但公司年均 46.46% 的盈利增長顯著超過了中國市場的整體擴張率，展示了其在激烈行業競爭和不斷變化的市場需求中的潛力。</p>
<ul>
<li>通過閲讀我們的健康報告，深入瞭解上海 OPM 生物科學的表現。</li>
<li>通過我們的詳細歷史表現報告評估上海 OPM 生物科學的過去表現。</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/24434bea-be79-43c0-b930-0c8e231fafe2/chart/earnings-and-revenue-growth?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" width="1642" height="1048" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/24434bea-be79-43c0-b930-0c8e231fafe2/chart/earnings-and-revenue-growth"/></p>
<p>SHSE:688293 截至 2025 年 12 月的盈利和收入增長</p>
<h2>Kakaku.com（TSE:2371）</h2>
<p><strong>Simply Wall St 增長評級：</strong> ★★★★☆☆</p>
<p><strong>概述：</strong> Kakaku.com, Inc.及其子公司在日本提供購買支持和餐廳評價服務，市值為 4543.3 億日元。</p>
<p><strong>運營：</strong> 該公司主要通過其 Kakaku.Com 部門產生收入，貢獻 240.4 億日元，以及 Tabelog 部門的 367.5 億日元，專注於日本的購買支持和餐廳評價。Kyujin Box 和孵化部門分別增加了 173.1 億日元和 89.1 億日元的額外收入，突顯了其在數字服務領域的多元化商業模式。</p>
<p>Kakaku.com 以其強大的價格比較和消費者服務平台而聞名，正在不斷變化的市場環境中保持着對創新的堅定承諾。公司年均 11.7% 的收入增長和 12.5% 的盈利增長超越了日本市場平均 4.6% 的擴張率。儘管在高增長領域並不處於領先地位，但 Kakaku.com 通過戰略性研發投資和高質量的盈利鞏固了其市場地位。近期持續分紅的確認彰顯了財務穩定性，吸引了尋求可靠回報的利益相關者。</p>
<ul>
<li>通過我們的綜合健康報告深入瞭解 Kakaku.com 的複雜性。</li>
<li>通過訪問我們的歷史表現報告評估 Kakaku.com 的過去表現。</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/5166ea84-bac7-4a4d-a803-a6652f4f9e2d/chart/earnings-and-revenue-growth?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" width="1642" height="1048" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/5166ea84-bac7-4a4d-a803-a6652f4f9e2d/chart/earnings-and-revenue-growth"/></p>
<p>TSE:2371 截至 2025 年 12 月的盈利和收入增長</p>
<h2>CELSYS（TSE:3663）</h2>
<p><strong>Simply Wall St 增長評級：</strong> ★★★★☆☆</p>
<p><strong>概述：</strong> CELSYS, Inc.在日本的內容創作解決方案領域運營，市值為 496.1 億日元。</p>
<p><strong>運營：</strong> CELSYS, Inc.專注於在日本提供內容創作解決方案。該公司主要通過軟件銷售和相關服務產生收入，專注於數字插圖、漫畫和動畫工具。</p>
<p>CELSYS 憑藉其戰略性的股票回購計劃吸引了關注，表明其對財務健康的信心和對股東價值的承諾。這一舉措與公司強勁的表現相輔相成，修訂後的盈利預測超出之前預期，得益於其旗艦軟件 CLIP STUDIO PAINT 的一次性購買和訂閲模式的強勁銷售。預計年均 27.2% 的盈利增長和每年 9% 的收入增長——均超過日本市場平均水平——使 CELSYS 在競爭激烈的科技領域中具備持續成功的潛力。</p>
<ul>
<li>點擊這裏訪問我們的完整健康分析報告，以瞭解 CELSYS 的動態。</li>
<li>通過我們的過去報告獲取 CELSYS 的趨勢和表現的見解。</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/850a7a11-e4be-477b-8270-7d157f2aada2/chart/earnings-and-revenue-growth?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" width="1642" height="1048" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/850a7a11-e4be-477b-8270-7d157f2aada2/chart/earnings-and-revenue-growth"/></p>
<p>TSE:3663 截至 2025 年 12 月的收益和收入增長</p>
<h2>利用優勢</h2>
<ul>
<li>在這裏發現 187 只亞洲高增長科技和人工智能股票的完整陣容。</li>
<li>這些股票中有哪一些是你資產組合的一部分嗎？利用 Simply Wall St 的投資組合分析能力，全面瞭解它們的發展情況。</li>
<li>Simply Wall St 是一款為長期股票投資者設計的革命性應用，免費且覆蓋全球所有市場。</li>
</ul>
<h2>對其他選項感興趣？</h2>
<ul>
<li>探索尚未獲得顯著分析師關注的高表現小型公司。</li>
<li>用顯示強勁增長潛力的公司來充實你的投資組合，這些公司得到了分析師和管理層的樂觀展望支持。</li>
<li>尋找現金流潛力良好但交易價格低於其公允價值的公司。</li>
</ul>
<p><em>這篇文章由 Simply Wall St 撰寫，內容具有一般性。<strong>我們提供基於歷史數據和分析師預測的評論，採用無偏見的方法，我們的文章並不構成財務建議。</strong> 這並不構成買入或賣出任何股票的推薦，也未考慮你的目標或財務狀況。我們的目標是為你提供以基本數據驅動的長期分析。請注意，我們的分析可能未考慮最新的價格敏感公司公告或定性材料。Simply Wall St 在提到的任何股票中沒有持倉。</em></p>

巨人網絡

科濟藥業-B

<p>亞洲科技股因其高增長潛力而備受關注，儘管經濟指標參差不齊。主要公司包括盛宜科技、巨人網絡集團和科濟藥業-B，均顯示出強勁的收入和盈利增長。上海 OPM 生物科學和 Kakaku.com 因其穩健的表現和戰略性研發投資而受到關注。CELSYS 因其股票回購計劃和強勁的銷售業績而受到認可。Simply Wall St 提供了對 187 只高增長科技股的全面分析</p>

<p>As Asian markets navigate a complex landscape marked by mixed economic indicators and evolving investor sentiment, the region's technology sector continues to capture attention with its potential for high growth. In this environment, identifying promising tech stocks involves looking for companies that demonstrate resilience and innovation amidst shifting global trends and local challenges.</p>
<div class="lb-trans"><p>隨着亞洲市場在複雜的環境中應對混合的經濟指標和不斷變化的投資者情緒，該地區的科技行業憑藉其高增長潛力繼續吸引關注。在這種環境下，識別有前景的科技股票需要尋找那些在全球趨勢變化和地方挑戰中展現出韌性和創新的公司。</p>
</div><h3>Top 10 High Growth Tech Companies In Asia</h3>
<div class="lb-trans"><h3>亞洲十大高增長科技公司</h3>
</div><table>
<thead>
<tr>
<th>Name</th>
<th>Revenue Growth</th>
<th>Earnings Growth</th>
<th>Growth Rating</th>
</tr>
</thead>
<tbody>
<tr>
<td>Shengyi TechnologyLtd</td>
<td>21.50%</td>
<td>32.87%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>Giant Network Group</td>
<td>34.73%</td>
<td>40.54%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>Fositek</td>
<td>37.83%</td>
<td>51.54%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>Suzhou TFC Optical Communication</td>
<td>35.80%</td>
<td>36.87%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>Gold Circuit Electronics</td>
<td>29.41%</td>
<td>37.22%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>Zhongji Innolight</td>
<td>34.82%</td>
<td>35.50%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>Shengyi Electronics</td>
<td>24.67%</td>
<td>33.32%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>eWeLLLtd</td>
<td>21.55%</td>
<td>22.80%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>Co-Tech Development</td>
<td>35.68%</td>
<td>75.80%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>CARsgen Therapeutics Holdings</td>
<td>100.40%</td>
<td>118.16%</td>
<td>★★★★★★</td>
</tr>
</tbody>
</table>
<div class="lb-trans"><table>
<thead>
<tr>
<th>名稱</th>
<th>收入增長</th>
<th>盈利增長</th>
<th>增長評級</th>
</tr>
</thead>
<tbody>
<tr>
<td>盛宜科技有限公司</td>
<td>21.50%</td>
<td>32.87%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>巨人網絡集團</td>
<td>34.73%</td>
<td>40.54%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>福斯特科技</td>
<td>37.83%</td>
<td>51.54%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>蘇州 TFC 光通信</td>
<td>35.80%</td>
<td>36.87%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>金電路電子</td>
<td>29.41%</td>
<td>37.22%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>中基光電</td>
<td>34.82%</td>
<td>35.50%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>盛宜電子</td>
<td>24.67%</td>
<td>33.32%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>eWeLL 有限公司</td>
<td>21.55%</td>
<td>22.80%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>科技發展</td>
<td>35.68%</td>
<td>75.80%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>CARsgen 治療控股</td>
<td>100.40%</td>
<td>118.16%</td>
<td>★★★★★★</td>
</tr>
</tbody>
</table>
</div><p>Click here to see the full list of 187 stocks from our Asian High Growth Tech and AI Stocks screener.</p>
<div class="lb-trans"><p>點擊這裏查看我們亞洲高增長科技和人工智能股票篩選器的完整 187 只股票列表。</p>
</div><p>We'll examine a selection from our screener results.</p>
<div class="lb-trans"><p>我們將從篩選結果中選取一些進行分析。</p>
</div><h2>Shanghai OPM Biosciences (SHSE:688293)</h2>
<div class="lb-trans"><h2>上海 OPM 生物科學（SHSE:688293）</h2>
</div><p><strong>Simply Wall St Growth Rating:</strong> ★★★★☆☆</p>
<div class="lb-trans"><p><strong>Simply Wall St 增長評級：</strong> ★★★★☆☆</p>
</div><p><strong>Overview:</strong> Shanghai OPM Biosciences Co., Ltd. is engaged in providing cell culture media and CDMO services both in China and internationally, with a market cap of CN¥5.90 billion.</p>
<div class="lb-trans"><p><strong>概述：</strong> 上海 OPM 生物科學有限公司專注於提供細胞培養基和 CDMO 服務，業務覆蓋中國及國際市場，市值為 59 億人民幣。</p>
</div><p><strong>Operations:</strong> OPM Biosciences generates revenue primarily through its cell culture media and CDMO services. The company operates both domestically in China and internationally, with a market cap of CN¥5.90 billion.</p>
<div class="lb-trans"><p><strong>運營：</strong> OPM 生物科學主要通過其細胞培養基和 CDMO 服務產生收入。該公司在中國和國際市場均有運營，市值為 59 億人民幣。</p>
</div><p>Shanghai OPM Biosciences has demonstrated robust growth in the competitive biotech sector, with a notable 25.8% increase in revenue to CNY 271.53 million and a surge in net income by 81.4% to CNY 49.43 million for the first nine months of 2025. These financial gains reflect a strategic emphasis on R&amp;D, crucial for maintaining technological leadership and innovation within Asia's high-growth markets. Despite facing challenges like a highly volatile share price and low forecasted Return on Equity at just 7%, the company's earnings growth of 46.46% annually outpaces the broader Chinese market's expansion rate significantly, showcasing its potential amidst fierce industry competition and evolving market demands.</p>
<div class="lb-trans"><p>上海 OPM 生物科學在競爭激烈的生物科技行業中展現出強勁的增長，2025 年前九個月收入顯著增長 25.8%，達到 2.7153 億人民幣，淨收入激增 81.4%，達到 4943 萬人民幣。這些財務收益反映出公司對研發的戰略重視，這對維持技術領導地位和在亞洲高增長市場中的創新至關重要。儘管面臨股價高度波動和預測的股本回報率僅為 7% 的挑戰，但公司年均 46.46% 的盈利增長顯著超過了中國市場的整體擴張率，展示了其在激烈行業競爭和不斷變化的市場需求中的潛力。</p>
</div><ul>
<li>Get an in-depth perspective on Shanghai OPM Biosciences' performance by reading our health report here.</li>
<li>Assess Shanghai OPM Biosciences' past performance with our detailed historical performance reports.</li>
</ul>
<div class="lb-trans"><ul>
<li>通過閲讀我們的健康報告，深入瞭解上海 OPM 生物科學的表現。</li>
<li>通過我們的詳細歷史表現報告評估上海 OPM 生物科學的過去表現。</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/24434bea-be79-43c0-b930-0c8e231fafe2/chart/earnings-and-revenue-growth" alt="" original-src="https://images.simplywall.st/company/24434bea-be79-43c0-b930-0c8e231fafe2/chart/earnings-and-revenue-growth"/></p>
<p>SHSE:688293 Earnings and Revenue Growth as at Dec 2025</p>
<div class="lb-trans"><p>SHSE:688293 截至 2025 年 12 月的盈利和收入增長</p>
</div><h2>Kakaku.com (TSE:2371)</h2>
<div class="lb-trans"><h2>Kakaku.com（TSE:2371）</h2>
</div><p><strong>Simply Wall St Growth Rating:</strong> ★★★★☆☆</p>
<div class="lb-trans"><p><strong>Simply Wall St 增長評級：</strong> ★★★★☆☆</p>
</div><p><strong>Overview:</strong> Kakaku.com, Inc., along with its subsidiaries, offers purchase support and restaurant review services in Japan and has a market capitalization of ¥454.33 billion.</p>
<div class="lb-trans"><p><strong>概述：</strong> Kakaku.com, Inc.及其子公司在日本提供購買支持和餐廳評價服務，市值為 4543.3 億日元。</p>
</div><p><strong>Operations:</strong> The company generates revenue primarily through its Kakaku.Com segment, contributing ¥24.04 billion, and Tabelog segment with ¥36.75 billion, focusing on purchase support and restaurant reviews in Japan. The Kyujin Box and Incubation segments add additional income streams of ¥17.31 billion and ¥8.91 billion respectively, highlighting a diversified business model within the digital services sector.</p>
<div class="lb-trans"><p><strong>運營：</strong> 該公司主要通過其 Kakaku.Com 部門產生收入，貢獻 240.4 億日元，以及 Tabelog 部門的 367.5 億日元，專注於日本的購買支持和餐廳評價。Kyujin Box 和孵化部門分別增加了 173.1 億日元和 89.1 億日元的額外收入，突顯了其在數字服務領域的多元化商業模式。</p>
</div><p>Kakaku.com, renowned for its robust platform in price comparison and consumer services, is navigating through an evolving market landscape with a steady commitment to innovation. With an 11.7% annual revenue growth and a 12.5% increase in earnings per year, the company outstrips Japan's average market expansion of 4.6%. Despite not leading the pack in high-growth sectors, Kakaku.com maintains a competitive edge through strategic R&amp;D investments and high-quality earnings that solidify its market position. Recent affirmations of consistent dividends underscore financial stability, appealing to stakeholders looking for reliable returns amidst dynamic market conditions.</p>
<div class="lb-trans"><p>Kakaku.com 以其強大的價格比較和消費者服務平台而聞名，正在不斷變化的市場環境中保持着對創新的堅定承諾。公司年均 11.7% 的收入增長和 12.5% 的盈利增長超越了日本市場平均 4.6% 的擴張率。儘管在高增長領域並不處於領先地位，但 Kakaku.com 通過戰略性研發投資和高質量的盈利鞏固了其市場地位。近期持續分紅的確認彰顯了財務穩定性，吸引了尋求可靠回報的利益相關者。</p>
</div><ul>
<li>Navigate through the intricacies of Kakaku.com with our comprehensive health report here.</li>
<li>Evaluate Kakaku.com's historical performance by accessing our past performance report.</li>
</ul>
<div class="lb-trans"><ul>
<li>通過我們的綜合健康報告深入瞭解 Kakaku.com 的複雜性。</li>
<li>通過訪問我們的歷史表現報告評估 Kakaku.com 的過去表現。</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/5166ea84-bac7-4a4d-a803-a6652f4f9e2d/chart/earnings-and-revenue-growth" alt="" original-src="https://images.simplywall.st/company/5166ea84-bac7-4a4d-a803-a6652f4f9e2d/chart/earnings-and-revenue-growth"/></p>
<p>TSE:2371 Earnings and Revenue Growth as at Dec 2025</p>
<div class="lb-trans"><p>TSE:2371 截至 2025 年 12 月的盈利和收入增長</p>
</div><h2>CELSYS (TSE:3663)</h2>
<div class="lb-trans"><h2>CELSYS（TSE:3663）</h2>
</div><p><strong>Simply Wall St Growth Rating:</strong> ★★★★☆☆</p>
<div class="lb-trans"><p><strong>Simply Wall St 增長評級：</strong> ★★★★☆☆</p>
</div><p><strong>Overview:</strong> CELSYS, Inc. operates in the content creation solutions sector in Japan and has a market capitalization of ¥49.61 billion.</p>
<div class="lb-trans"><p><strong>概述：</strong> CELSYS, Inc.在日本的內容創作解決方案領域運營，市值為 496.1 億日元。</p>
</div><p><strong>Operations:</strong> CELSYS, Inc. specializes in providing content creation solutions within Japan. The company generates revenue primarily through software sales and related services, focusing on digital illustration, manga, and animation tools.</p>
<div class="lb-trans"><p><strong>運營：</strong> CELSYS, Inc.專注於在日本提供內容創作解決方案。該公司主要通過軟件銷售和相關服務產生收入，專注於數字插圖、漫畫和動畫工具。</p>
</div><p>CELSYS is capturing attention with its strategic share repurchase program, signaling confidence in its financial health and commitment to shareholder value. This initiative complements the company's robust performance, highlighted by a revised earnings forecast that surpasses previous expectations due to strong sales from both one-time purchases and subscription models of its flagship software, CLIP STUDIO PAINT. With an impressive 27.2% expected annual earnings growth and a revenue increase of 9% per year—outpacing the Japanese market average—CELSYS is poised for continued success in the competitive tech landscape.</p>
<div class="lb-trans"><p>CELSYS 憑藉其戰略性的股票回購計劃吸引了關注，表明其對財務健康的信心和對股東價值的承諾。這一舉措與公司強勁的表現相輔相成，修訂後的盈利預測超出之前預期，得益於其旗艦軟件 CLIP STUDIO PAINT 的一次性購買和訂閲模式的強勁銷售。預計年均 27.2% 的盈利增長和每年 9% 的收入增長——均超過日本市場平均水平——使 CELSYS 在競爭激烈的科技領域中具備持續成功的潛力。</p>
</div><ul>
<li>Click here and access our complete health analysis report to understand the dynamics of CELSYS.</li>
<li>Gain insights into CELSYS' past trends and performance with our Past report.</li>
</ul>
<div class="lb-trans"><ul>
<li>點擊這裏訪問我們的完整健康分析報告，以瞭解 CELSYS 的動態。</li>
<li>通過我們的過去報告獲取 CELSYS 的趨勢和表現的見解。</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/850a7a11-e4be-477b-8270-7d157f2aada2/chart/earnings-and-revenue-growth" alt="" original-src="https://images.simplywall.st/company/850a7a11-e4be-477b-8270-7d157f2aada2/chart/earnings-and-revenue-growth"/></p>
<p>TSE:3663 Earnings and Revenue Growth as at Dec 2025</p>
<div class="lb-trans"><p>TSE:3663 截至 2025 年 12 月的收益和收入增長</p>
</div><h2>Taking Advantage</h2>
<div class="lb-trans"><h2>利用優勢</h2>
</div><ul>
<li>Discover the full array of 187 Asian High Growth Tech and AI Stocks right here.</li>
<li>Are any of these part of your asset mix? Tap into the analytical power of Simply Wall St's portfolio to get a 360-degree view on how they're shaping up.</li>
<li>Simply Wall St is a revolutionary app designed for long-term stock investors, it's free and covers every market in the world.</li>
</ul>
<div class="lb-trans"><ul>
<li>在這裏發現 187 只亞洲高增長科技和人工智能股票的完整陣容。</li>
<li>這些股票中有哪一些是你資產組合的一部分嗎？利用 Simply Wall St 的投資組合分析能力，全面瞭解它們的發展情況。</li>
<li>Simply Wall St 是一款為長期股票投資者設計的革命性應用，免費且覆蓋全球所有市場。</li>
</ul>
</div><h2>Curious About Other Options?</h2>
<div class="lb-trans"><h2>對其他選項感興趣？</h2>
</div><ul>
<li>Explore high-performing small cap companies that haven't yet garnered significant analyst attention.</li>
<li>Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management.</li>
<li>Find companies with promising cash flow potential yet trading below their fair value.</li>
</ul>
<div class="lb-trans"><ul>
<li>探索尚未獲得顯著分析師關注的高表現小型公司。</li>
<li>用顯示強勁增長潛力的公司來充實你的投資組合，這些公司得到了分析師和管理層的樂觀展望支持。</li>
<li>尋找現金流潛力良好但交易價格低於其公允價值的公司。</li>
</ul>
</div><p><em>This article by Simply Wall St is general in nature. <strong>We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.</strong> It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.</em></p>
<div class="lb-trans"><p><em>這篇文章由 Simply Wall St 撰寫，內容具有一般性。<strong>我們提供基於歷史數據和分析師預測的評論，採用無偏見的方法，我們的文章並不構成財務建議。</strong> 這並不構成買入或賣出任何股票的推薦，也未考慮你的目標或財務狀況。我們的目標是為你提供以基本數據驅動的長期分析。請注意，我們的分析可能未考慮最新的價格敏感公司公告或定性材料。Simply Wall St 在提到的任何股票中沒有持倉。</em></p>
</div>

2025 年 12 月亞洲高增長科技股值得關注